Segments (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Segment Reporting [Abstract] |
|
| Summary of Segment Profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
Revenues |
|
$ |
7,690 |
|
|
$ |
5,040 |
|
|
$ |
2,162 |
|
Cost of sales |
|
|
2,236 |
|
|
|
2,293 |
|
|
|
1,116 |
|
R&D expenses |
|
|
633 |
|
|
|
247 |
|
|
|
103 |
|
S&M expenses |
|
|
1,051 |
|
|
|
902 |
|
|
|
475 |
|
G&A expenses |
|
|
456 |
|
|
|
295 |
|
|
|
147 |
|
Other |
|
|
1 |
|
|
|
1 |
|
|
|
(14 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment profit |
|
$ |
3,313 |
|
|
$ |
1,303 |
|
|
$ |
336 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
Revenues |
|
$ |
6,498 |
|
|
$ |
5,103 |
|
|
$ |
2,463 |
|
Cost of sales |
|
|
2,312 |
|
|
|
2,197 |
|
|
|
1,229 |
|
R&D expenses |
|
|
633 |
|
|
|
229 |
|
|
|
112 |
|
S&M expenses |
|
|
925 |
|
|
|
826 |
|
|
|
534 |
|
G&A expenses |
|
|
407 |
|
|
|
272 |
|
|
|
150 |
|
Other |
|
|
2 |
|
|
|
3 |
|
|
|
(2 |
) |
Segment profit |
|
$ |
2,219 |
|
|
$ |
1,575 |
|
|
$ |
440 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
Revenues |
|
$ |
6,154 |
|
|
$ |
4,837 |
|
|
$ |
2,351 |
|
Cost of sales |
|
|
2,051 |
|
|
|
2,111 |
|
|
|
1,191 |
|
R&D expenses |
|
|
604 |
|
|
|
220 |
|
|
|
104 |
|
S&M expenses |
|
|
813 |
|
|
|
767 |
|
|
|
487 |
|
G&A expenses |
|
|
373 |
|
|
|
263 |
|
|
|
142 |
|
Other |
|
|
(2 |
) |
|
|
(2 |
) |
|
|
(39 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment profit |
|
$ |
2,315 |
|
|
$ |
1,478 |
|
|
$ |
465 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States profit |
|
$ |
3,313 |
|
|
$ |
2,219 |
|
|
$ |
2,315 |
|
Europe profit |
|
|
1,303 |
|
|
|
1,575 |
|
|
|
1,478 |
|
International Markets profit |
|
|
336 |
|
|
|
440 |
|
|
|
465 |
|
Total reportable segments profit |
|
|
4,952 |
|
|
|
4,234 |
|
|
|
4,258 |
|
Profit (loss) of Other Activities |
|
|
(47 |
) |
|
|
96 |
|
|
|
103 |
|
Amounts not allocated to segments: |
|
|
|
|
|
|
|
|
|
|
|
|
Amortization |
|
|
581 |
|
|
|
588 |
|
|
|
616 |
|
Other assets impairments, restructuring and other items |
|
|
1,050 |
|
|
|
1,388 |
|
|
|
718 |
|
Goodwill impairment |
|
|
— |
|
|
|
1,280 |
|
|
|
700 |
|
Intangible asset impairments |
|
|
259 |
|
|
|
251 |
|
|
|
350 |
|
Legal settlements and loss contingencies |
|
|
473 |
|
|
|
761 |
|
|
|
1,043 |
|
Other unallocated amounts |
|
|
384 |
|
|
|
364 |
|
|
|
502 |
|
Consolidated operating income (lo ss ) |
|
|
2,157 |
|
|
|
(303 |
) |
|
|
433 |
|
Financial expenses, net |
|
|
934 |
|
|
|
981 |
|
|
|
1,057 |
|
Consolidated income (loss) before income taxes |
|
$ |
1,223 |
|
|
$ |
(1,284 |
) |
|
$ |
(624 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule Of Consolidated Income Before Income Tax |
|
Segment revenues by major products and activities: | The following tables present revenues by major products and activities for each segment for the year ended December 31, 2025, 2024 and 2023:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Generic products (including biosimilars) |
|
$ |
3,657 |
|
|
$ |
3,599 |
|
|
$ |
3,138 |
|
AJOVY |
|
|
295 |
|
|
|
207 |
|
|
|
211 |
|
AUSTEDO |
|
|
2,217 |
|
|
|
1,642 |
|
|
|
1,225 |
|
BENDEKA and TREANDA |
|
|
147 |
|
|
|
168 |
|
|
|
237 |
|
COPAXONE |
|
|
255 |
|
|
|
242 |
|
|
|
297 |
|
UZEDY |
|
|
191 |
|
|
|
117 |
|
|
|
23 |
|
Other* |
|
|
929 |
|
|
|
523 |
|
|
|
1,024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
7,690 |
|
|
$ |
6,498 |
|
|
$ |
6,154 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * |
Other revenues in 2025 were mainly comprised of milestone payments of $500 million received in the fourth quarter of 2025, in connection with the initiation of Phase 3 studies for duvakitug (anti-TL1A) (see note 2 ). Other revenues in 2024 include the sale of certain product rights. Other revenues in 2023 were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s duvakitug (anti-TL1A) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Generic products (including OTC and biosimilars) |
|
$ |
4,044 |
|
|
$ |
3,926 |
|
|
$ |
3,664 |
|
AJOVY |
|
|
270 |
|
|
|
216 |
|
|
|
160 |
|
COPAXONE |
|
|
181 |
|
|
|
213 |
|
|
|
231 |
|
Respiratory products |
|
|
227 |
|
|
|
244 |
|
|
|
265 |
|
Other* |
|
|
319 |
|
|
|
504 |
|
|
|
516 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
5,040 |
|
|
$ |
5,103 |
|
|
$ |
4,837 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * |
Other revenues in 2025, 2024 and 2023 include the sale of certain product rights. | International Markets segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Generic products (including OTC and biosimilars) |
|
$ |
1,721 |
|
|
$ |
1,937 |
|
|
$ |
1,932 |
|
| AJOVY |
|
|
108 |
|
|
|
84 |
|
|
|
63 |
|
| AUSTEDO |
|
|
43 |
|
|
|
46 |
|
|
|
15 |
|
| COPAXONE |
|
|
32 |
|
|
|
48 |
|
|
|
63 |
|
| Other* |
|
|
259 |
|
|
|
349 |
|
|
|
278 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total |
|
$ |
2,162 |
|
|
$ |
2,463 |
|
|
$ |
2,351 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Sales Percentage by Therapeutic Category |
The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2025, 2024 and 2023.
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Percentage of Third Party Net Sales |
|
| |
|
|
|
|
|
|
|
|
|
| McKesson Corporation |
|
|
13 |
% |
|
|
12 |
% |
|
|
9 |
% |
| AmerisourceBergen Corporation |
|
|
11 |
% |
|
|
9 |
% |
|
|
9 |
% | Most of Teva’s revenues from these customers were in the United States segment.
|
| Schedule of Property, Plant and Equipment by Geographic Location |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Israel |
|
$ |
1,033 |
|
|
$ |
1,066 |
|
| Germany |
|
|
704 |
|
|
|
1,262 |
|
| United States |
|
|
529 |
|
|
|
561 |
|
| Croatia |
|
|
312 |
|
|
|
277 |
|
| Czech Republic |
|
|
199 |
|
|
|
206 |
|
| Hungary |
|
|
86 |
|
|
|
83 |
|
| Ireland |
|
|
244 |
|
|
|
261 |
|
| Other |
|
|
973 |
|
|
|
865 |
|
|
|
|
|
|
|
|
|
|
| Total property, plant and equipment |
|
$ |
4,080 |
|
|
$ |
4,581 |
|
|
|
|
|
|
|
|
|
|
|